CD33 and acute myeloid leukemia: Since FOLR1-directed CAR T cells do not impact normal hematopoiesis, targeting FOLR1 would in principle not lead to prolonged myelosuppression or myeloablation, which are significant barriers for current CAR T therapy in AML targeting lineage markers CD33 and CD123.